Company: SWKH
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001628280-25-025955
Chunk: 42

Company: SWK Holdings Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 42
---
 manages its operations. Please refer to Item 1. Financial Statements, Note 9 of the notes to the unaudited condensed consolidated financial statements for further information regarding segment information.

23

Finance Receivables Portfolio Overview

The table below provides an overview of our outstanding finance receivables transactions as of and for the three months ended March 31, 2025 (in thousands, except rate, share and per share data):

Revenue RecognizedRoyalty PurchasesLicensed TechnologyFunded AmountGAAP BalanceYear-to-DateBesivance® (1) Ophthalmic antibiotic$6,000 $— $2 Forfivo XL® (7)Depressive disorder treatment6,000 1,110 506 Coflex®/Kybella® (7)Spinal stenosis/submental fullness4,350 2,702 48 Cambia® (4) (7)NSAID migraine treatment8,500 — 98 Duo Royalty (7)Japanese Women's health/cystic fibrosis15,353 10,083 591 Immune Globulin (7)Immune Globulin Therapeutics 14,100 10,452 443 Relief (7)Rare Disease Portfolio7,701 7,331 336 Best ABT, Inc.(2), (3)Oncology diagnosis 5,784 2,347 — Flowonix Medical, Inc.(2), (3), (5)Drug delivery device 12,455 7,433 — Ideal Implant, Inc.(2), (3)Aesthetics 4,025 3,039 — Iluvien® (8)Diabetic macular edema16,501 — 519 Revenue RecognizedTerm LoansTypeMaturity DatePrincipalGAAP BalanceRateYear-to-Date4Web, Inc.First lien06/30/25$20,336 $23,238 12.8%$944 AOTI, Inc.First lien03/21/278,478 8,674 11.2%342 Elutia, Inc.First lien08/10/2721,045 24,351 12.0%891 Biotricity, Inc.First lien02/15/2714,446 14,876 11.5%675 CDMO ManufacturerFirst lien09/13/275,000 5,